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Legalisation of non-medical cannabis in Canada: will supply 
regulations effectively serve public health? 
A major social and health policy experiment will begin 
in Canada on July 1, 2018: the legalisation of non-
medical cannabis.1 This major national cannabis policy 
reform, which is unique in the G20, has been framed 
by the fundamental objective to protect and improve 
cannabis-related public health and safety.1 
The prospective success of achieving this goal is an 
open question, as indicated by emerging evidence from 
other jurisdictions undergoing legalisation experiments.2 
Although much attention has been on possible adverse 
outcomes related to use (eg, use in young people, 
impaired driving, and brain and mental health harms), 
the possible effects of cannabis legalisation will depend 
on many implementation details, including effective 
regulation of cannabis production and retail distri-
bution.3 This regulation constitutes a complex challenge, 
for several reasons, especially in the Canadian context. 
On one hand, there are obvious good reasons to restrict 
cannabis production and distribution as tightly as 
possible for the benefits of limiting consumption and 
related harms. At the same time, the public health and 
safety effects of legalisation will crucially hinge on its 
success in effectively shifting users from illegal to legal 
distribution environments, with the latter offering 
products that are quality controlled and predictable, and 
as low risk as possible. 
However, conditions for legalised cannabis production 
and distribution are not being developed on neutral 
grounds in Canada. Rather, they are being built in the 
long-existing context of both flourishing black markets 
and extensive supply structures for medical cannabis, 
including hundreds of illegal dispensaries across 
Canada, which have evolved to expand their cannabis 
distribution far beyond supply for therapeutic purposes.4 
Furthermore, jurisdictional challenges exist: although 
cannabis legalisation in Canada is principally enabled 
by federal legislation, many of its key practical details, 
especially regarding retail distribution, will be defined by 
provincial regulations, possibly creating lateral and vertical 
inconsistencies or tensions.
Some of these tensions are already emerging or 
present. Even before legislation of non-medical cannabis, 
a vast and rapidly growing landscape of (currently >60) 
licensed producers of cannabis exist and are functioning 
under Canada’s national medical cannabis distribution 
regime.5 This industry expects production of non-medical 
cannabis to be its primary future business and profit 
source. On this basis, the existing commercial cannabis 
industry is keen to keep its future marketplace and 
products as unencumbered as possible from regulatory 
restrictions, including those focusing on product types, 
advertising and promotion, and restrictions on sales—all 
of which are factors that influence use and subsequent 
harm outcomes, as ample evidence from alcohol and 
tobacco control shows.6,7 
Regulations for recreational cannabis retail distribution 
in Ontario, Canada’s most populous province, propose 
to restrict distribution under a public monopoly and to 
operate a limited number of government-controlled 
outlets (similar to, but separate from the provincially-
owned alcohol retail monopoly).8 However, these plans 
overlook the possible regulation and integration of the 
many existent private  community-storefront cannabis 
dispensaries, which could therefore continue to operate 
illegally in competition with state-run outlets. Other 
provinces are still developing their cannabis retail 
distribution schemes, which might evolve to be different 
from Ontario’s and, for example, provide to include 
private retail outlets. 
Supply provisions for legislation of non-medical 
cannabis in Canada comprise another distinct element. 
The federal cannaabis legalisation bill includes 
provisions for home-growing of up to four cannabis 
plants per adult household in private homes. Such 
provisions would be extremely difficult to monitor and 
enforce, and so could allow many (including underage) 
people access to mainly unregulated cannabis products, 
and also expose many non-users to the adverse 
consequences of cannabis growing and use in domestic 
environments.
As extensive experiences from other fields show, the 
restrictions around production and retail distribution 
of psychoactive products for recreational consumption 
strongly influence population-level use and health 
outcomes.7,9 Empirical evidence on these fronts in the 
cannabis arena is scarce, but includes (rather conflicting) 
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experiences. In the USA, commercialised approaches to 
distribution of legalised cannabis have been associated 
with a variety of public health-relevant problems.2 
In Uruguay, a starkly restricted system for distribution 
of legal cannabis (eg, including user registration and 
restricted product and distribution options) has been 
rejected by many users, thus lowering its potential for 
achievement of optimal public health benefits.10
Effective regulation of cannabis supply and distribution 
constitutes a pivotal determinant of the success of 
cannabis legalisation towards public health outcomes. 
Regulations must strike a meaningful balance between 
tightly restricting products and availability, while 
simultaneously creating a legal supply environment that 
is appealing and accessible for consumers to actively 
embrace and utilise. Whether existing legalisation 
regimes have yet found that balance is an open question, 
and it remains to be seen whether the proposed plans 
for Canada will succeed. These emerging lessons are also 
relevant for other jurisdictions contemplating similar 
fundamental cannabis policy reforms.
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